Application

Dosage Regimen for a Controlled-Release PTH Compound

Patent Number US-20230321198-A1

Publication Year 2023

Application Year 2023

Priority Year 2016

Jurisdiction US

Status Pending

Inventors

SPROGÿE KENNETT CLEEMANN FELIX MAITRO GUILLAUME KRUSCH MATHIAS WEGGE THOMAS ZETTLER JOACHIM

Applicants

  1. Ascendis Pharma Bone Diseases AS
  2. [NORA names: Ascendis Pharma; Private Research]

Abstract

The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTII compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTII compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequent than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTII 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.

Patent Family Records (38)

Controlled-release PTH compound  

Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)

2024, US-11918628-B2

Controlled-release PTH compound  

Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)

2024, US-11890326-B2

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES A HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGE KENNETT, (...more)

2024, KR-20240013849-A

Dosage Regimen for Controlled Release PTH Compounds  

아센디스 파마 본 디지즈 에이/에스 КАРПФ, Дэвид Брайан, СПРОГЕЕ, Кеннетт, ХОЛЬТЕН-АНДЕРСЕН, Ларс, (...more)

2024, KR-102627405-B1

DOSAGE REGIMEN FOR CONTROLLED-RELEASE PTH COMPOUND  

Ascendis Pharma Bone Diseases AS LARS HOLTEN-ANDERSEN, KENNETT SPROGOE, DAVID BRIAN KARPF

2024, JP-2024041859-A

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)

2024, HU-E063235-T2

Dosing regimen for a controlled release pth compound  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2024, ES-2959995-T3

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2024, EP-4275677-A3

Dosage regimen for controlled release of PTH compounds  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)

2024, CN-117838873-A

Dosage regimen for controlled release of PTH compounds  

Ascendis Pharma Bone Diseases AS L. Holden-Anderson, SPROGOEE KENNETT, D.B. Kapf

2024, CN-109789189-B

Controlled-Release PTH Compound  

Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)

2023, US-20230381284-A1

Dosage Regimen for a Controlled-Release PTH Compound

Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)

2023, US-20230321198-A1

Dosage Regimen for a Controlled-Release PTH Compound  

Ascendis Pharma Bone Diseases AS SPROGÿE KENNETT, SPROGØE KENNETT, CLEEMANN FELIX, (...more)

2023, US-20230248836-A1

Dosage regimen for a controlled-release PTH compound  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2023, US-11590207-B2

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)

2023, SI-3518960-T1

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2023, RS-64440-B1

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2023, PL-3518960-T3

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2023, LT-3518960-T

Dosing Regimens for Controlled-Release PTH Compounds  

Ascendis Pharma Bone Diseases AS LARS HOLTEN-ANDERSEN, KENNETT SPROGOE, DAVID BRIAN KARPF

2023, JP-2023017796-A

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS

2023, IL-304086-A

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS

2023, IL-265591-B2

Dosage regimen for a controlled-release pth compound  

ASCENDIS PHARMA BONE DISEASES AS

2023, IL-265591-B1

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2023, HR-P20231079-T1

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2023, EP-4275677-A2

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2023, EP-3518960-B1

Dosage schedule for a controlled release PTH compound  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, KARPF DAVID BRIAN, (...more)

2023, DK-3518960-T3

Dosage Regimen for a Controlled-Release PTH Compound  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2020, US-20200023041-A1

CONTROLLED RELEASE PTH CONNECTION DOSING MODE  

Асцендис Фарма Боун Дизизис А/С КАРПФ, Дэвид Брайан, СПРОГЕЕ, Кеннетт, ХОЛЬТЕН-АНДЕРСЕН, Ларс, (...more)

2020, RU-2019112913-A

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2019, ZA-201901811-B

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2019, SG-11201901576Q-A

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND.  

ASCENDIS PHARMA BONE DISEASES AS KENNETT SPROGØE, LARS HOLTEN-ANDERSEN, DAVID BRIAN KARPF

2019, MX-2019003181-A

Dosage regimen for controlled-release PTH compound  

ASCENDIS PHARMA BONE DISEASES A HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2019, KR-20190062496-A

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2019, EP-3518960-A1

The dosage of controlled release PTH compound  

Arsendis Drug Bone Disease Co Ltd HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)

2019, CN-109789189-A

dosing regimen for a controlled release pth compound  

ASCENDIS PHARMA BONE DISEASES AS DAVID BRIAN KARPF, KENNETT SPROGØE, LARS HOLTEN-ANDERSEN

2019, BR-112019005533-A2

Dosage regimen for a controlled-release PTH compound  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2019, AU-2017336249-A1

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

ASCENDIS PHARMA BONE DISEASES AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGÿE KENNETT, (...more)

2018, WO-2018060310-A1

DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND  

Ascendis Pharma Bone Diseases AS HOLTEN ANDERSEN LARS, HOLTEN-ANDERSEN LARS, SPROGOE KENNETT, (...more)

2018, CA-3037442-A1

Data Provider: Digital Science